Engineering and Design of Chimeric Antigen Receptors
Sònia GuedanDepartment of Hematology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, SpainHugo CalderónDepartment of Hematology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, SpainAvery D. PoseyCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAMarcela V. MausCellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
2018en
ABI
Аннотация
T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since the first clinical reports of their efficacy emerged 7 years ago, investigators have focused on the mechanisms and properties that make CARs effective or toxic, and their effects on T cell biology. Novel CAR designs coupled with improvements in gene transfer technology, incorporating advances in gene editing, have the potential to increase access to engineered cell therapies, as well as improve their potency in solid tumors.
Ҳали таржима қилинмаган
Идентификаторлар
Иқтибослар ва манбалар
3 та иқтибос0 та фойдаланилган манба